
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator in... InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.34 | -21.3836477987 | 1.59 | 1.64 | 1.24 | 440451 | 1.40169626 | CS |
4 | -1.2 | -48.9795918367 | 2.45 | 2.77 | 1.24 | 610472 | 1.94522833 | CS |
12 | -1.32 | -51.3618677043 | 2.57 | 2.77 | 1.24 | 364391 | 2.1295304 | CS |
26 | -0.34 | -21.3836477987 | 1.59 | 2.815 | 1.24 | 270692 | 2.07357044 | CS |
52 | -0.46 | -26.9005847953 | 1.71 | 2.815 | 1.165 | 206930 | 1.87347267 | CS |
156 | -1.04 | -45.4148471616 | 2.29 | 7.2499 | 0.7762 | 424836 | 3.6790706 | CS |
260 | -3.45 | -73.4042553191 | 4.7 | 9.7 | 0.7762 | 586109 | 4.18549408 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.